Klaus Nave PhD, Director of the Max Planck Institute of Experimental Medicine, discusses the emerging role of oligodendrocytes in ALS and potential treatment strategies going forward. Read more: http://blogs.als.net/post/2012/10/29/ALS-dressed-to-the-C9s.aspx